Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
110 hedge funds and large institutions have $246M invested in Accelerate Diagnostics in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 10 closing their positions.
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
1% more funds holding
Funds holding: 109 → 110 (+1)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
51% less call options, than puts
Call options by funds: $1.56M | Put options by funds: $3.21M
52% less capital invested
Capital invested by funds: $513M → $246M (-$267M)
Top Buyers
| 1 |
GAM
Griffin Asset Management
New York
|
+$5.57M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.55M |
| 3 |
Two Sigma Investments
New York
|
+$1.34M |
| 4 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$1.32M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$889K |
Top Sellers
| 1 |
Stifel Financial
St. Louis,
Missouri
|
-$6.04M |
| 2 |
CC
Chicago Capital
Chicago,
Illinois
|
-$5.86M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.38M |
| 4 |
Morgan Stanley
New York
|
-$3.08M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.8M |
AXDX Hedge Fund Activity: Q1 2020 in Review
110 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2020, worth a combined $246M — down 52% from $513M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AXDX positions and 10 closed out — a net gain of 4 holders — while 32 added to existing stakes and 27 trimmed.
The largest buyer was Griffin Asset Management, adding an estimated $5.57M. The largest seller was Stifel Financial, cutting an estimated $6.04M.
- 110 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2020, up from 109 in Q4 2019.
- Funds reported $246M of Accelerate Diagnostics stock for Q1 2020, down 52% quarter-over-quarter.
- 14 funds opened new Accelerate Diagnostics positions in Q1 2020 and 10 closed out, a net change of +4 holders.
- The largest Accelerate Diagnostics buyer in Q1 2020 was Griffin Asset Management, an estimated $5.57M added.
- The largest Accelerate Diagnostics seller in Q1 2020 was Stifel Financial, an estimated $6.04M sold.
Based on aggregated 13F filings for Q1 2020.